The oncolytic effect of recombinant vesicular stomatitis virus is enhanced by expression of the fusion cytosine deaminase/uracil phosphoribosyltransferase suicide gene - PubMed (original) (raw)

. 2003 Dec 1;63(23):8366-76.

Affiliations

PMID: 14678998

The oncolytic effect of recombinant vesicular stomatitis virus is enhanced by expression of the fusion cytosine deaminase/uracil phosphoribosyltransferase suicide gene

Mercedes Porosnicu et al. Cancer Res. 2003.

Abstract

Vesicular stomatitis virus (VSV) has recently been demonstrated to exhibit significant oncolytic capabilities against a wide variety of tumor models in vitro and in vivo. To potentially enhance the oncolytic effect, we generated a novel recombinant VSV (rVSV) that expressed the fusion suicide gene Escherichia coli cytosine deaminase (CD)/uracil phosphoribosyltransferase (UPRT). rVSV encoding the CD/UPRT fusion gene (VSV-C:U) exhibited normal growth properties and generated high levels of biologically active CD/UPRT that could catalyze the modification of 5-fluorocytosine into chemotherapeutic 5-fluorouracil (5-FU), which exhibited considerable bystander effect. Intratumoral inoculation of VSV-C:U in the presence of the systemically administered prodrug 5-fluorocytosine produced statistically significant reductions in the malignant growth of syngeneic lymphoma (A20) or mammary carcinoma (TSA) in BALB/c mice compared with rVSV treatments or with control 5-FU alone. Aside from detecting prolonged therapeutic levels of 5-FU in VSV-C:U-treated animals harboring TSA tumors and enhancing bystander killing of tumor cells, we demonstrated marked activation of IFN-gamma-secreting cytotoxic T cells by enzyme-linked immunospot analysis that may have also facilitated tumor killing. In conclusion, the insertion of the fusion CD/UPRT suicide gene potentiates the oncolytic efficiency of VSV by generating a strong bystander effect and by contributing to the activation of the immune system against the tumor without detrimentally altering the kinetics of virus-mediated oncolysis and may be useful in the treatment of malignant disease.

PubMed Disclaimer

Cited by

MicroRNA-sensitive oncolytic measles virus for chemovirotherapy of pancreatic cancer.
Singh HM, Leber MF, Bossow S, Engeland CE, Dessila J, Grossardt C, Zaoui K, Bell JC, Jäger D, von Kalle C, Ungerechts G. Singh HM, et al. Mol Ther Oncolytics. 2021 May 5;21:340-355. doi: 10.1016/j.omto.2021.04.015. eCollection 2021 Jun 25. Mol Ther Oncolytics. 2021. PMID: 34141871 Free PMC article.
Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model.
De Giovanni C, Nicoletti G, Landuzzi L, Palladini A, Lollini PL, Nanni P. De Giovanni C, et al. Cancers (Basel). 2019 Nov 27;11(12):1889. doi: 10.3390/cancers11121889. Cancers (Basel). 2019. PMID: 31783695 Free PMC article. Review.
Oncotargeting by Vesicular Stomatitis Virus (VSV): Advances in Cancer Therapy.
Bishnoi S, Tiwari R, Gupta S, Byrareddy SN, Nayak D. Bishnoi S, et al. Viruses. 2018 Feb 23;10(2):90. doi: 10.3390/v10020090. Viruses. 2018. PMID: 29473868 Free PMC article. Review.
Control of Human T-Cell Leukemia Virus Type 1 (HTLV-1) Infection by Eliminating Envelope Protein-Positive Cells with Recombinant Vesicular Stomatitis Viruses Encoding HTLV-1 Primary Receptor.
Tezuka K, Okuma K, Kuramitsu M, Matsuoka S, Tanaka R, Tanaka Y, Hamaguchi I. Tezuka K, et al. J Virol. 2018 Jan 30;92(4):e01885-17. doi: 10.1128/JVI.01885-17. Print 2018 Feb 15. J Virol. 2018. PMID: 29212930 Free PMC article.
VSV based virotherapy in ovarian cancer: the past, the present and …future?
Orzechowska BU, Jędryka M, Zwolińska K, Matkowski R. Orzechowska BU, et al. J Cancer. 2017 Jul 22;8(12):2369-2383. doi: 10.7150/jca.19473. eCollection 2017. J Cancer. 2017. PMID: 28819441 Free PMC article. Review.

The oncolytic effect of recombinant vesicular stomatitis virus is enhanced by expression of the fusion cytosine deaminase/uracil phosphoribosyltransferase suicide gene - PubMed (original) (raw)